Profund Advisors LLC Has $20.84 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Profund Advisors LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 11.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 287,002 shares of the biopharmaceutical company’s stock after selling 35,997 shares during the quarter. Gilead Sciences accounts for about 0.7% of Profund Advisors LLC’s holdings, making the stock its 26th biggest position. Profund Advisors LLC’s holdings in Gilead Sciences were worth $20,839,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the business. OLD Second National Bank of Aurora lifted its stake in Gilead Sciences by 46.3% in the third quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 139 shares during the period. Impax Asset Management Group plc increased its holdings in Gilead Sciences by 0.4% in the 3rd quarter. Impax Asset Management Group plc now owns 40,201 shares of the biopharmaceutical company’s stock worth $2,808,000 after buying an additional 149 shares in the last quarter. Key Financial Inc boosted its position in Gilead Sciences by 3.7% in the fourth quarter. Key Financial Inc now owns 4,228 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 151 shares during the last quarter. Trust Investment Advisors boosted its position in Gilead Sciences by 1.3% in the fourth quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 153 shares during the last quarter. Finally, Equitable Holdings Inc. lifted its holdings in Gilead Sciences by 0.4% in the 3rd quarter. Equitable Holdings Inc. now owns 41,253 shares of the biopharmaceutical company’s stock worth $2,882,000 after purchasing an additional 156 shares in the last quarter. Institutional investors and hedge funds own 79.00% of the company’s stock.

Gilead Sciences stock traded up $0.04 during mid-day trading on Tuesday, hitting $62.69. 100,773 shares of the company’s stock were exchanged, compared to its average volume of 10,590,126. The firm has a market capitalization of $78.61 billion, a P/E ratio of 12.71, a PEG ratio of 0.46 and a beta of 0.40. Gilead Sciences, Inc. has a fifty-two week low of $57.19 and a fifty-two week high of $74.12. The company has a quick ratio of 1.13, a current ratio of 1.27 and a debt-to-equity ratio of 1.24. The company’s 50 day simple moving average is $60.55 and its 200-day simple moving average is $65.84.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Tuesday, February 1st. The biopharmaceutical company reported $0.69 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.53 by ($0.84). Gilead Sciences had a net margin of 22.80% and a return on equity of 45.27%. The company had revenue of $7.24 billion during the quarter, compared to the consensus estimate of $6.64 billion. During the same quarter in the previous year, the business earned $2.19 EPS. Gilead Sciences’s revenue was down 2.4% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 6.53 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 30th. Shareholders of record on Tuesday, March 15th were paid a dividend of $0.73 per share. The ex-dividend date was Monday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.71. This represents a $2.92 annualized dividend and a yield of 4.66%. Gilead Sciences’s dividend payout ratio is presently 59.23%.

Several equities analysts have commented on the company. StockNews.com initiated coverage on Gilead Sciences in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Morgan Stanley decreased their target price on Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. Piper Sandler lifted their price objective on Gilead Sciences from $71.00 to $72.00 in a research note on Tuesday, April 12th. Maxim Group dropped their target price on shares of Gilead Sciences from $88.00 to $84.00 in a research report on Thursday, February 3rd. Finally, Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 22nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $73.31.

In other news, EVP Brett A. Pletcher sold 14,061 shares of the stock in a transaction dated Tuesday, February 1st. The shares were sold at an average price of $68.54, for a total transaction of $963,740.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $58.24, for a total transaction of $211,644.16. The disclosure for this sale can be found here. Insiders have sold 19,386 shares of company stock valued at $1,283,423 over the last quarter. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.